Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.52 |
| ▸ | PDE4A | P27815 | 3/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.38 |
| ▸ | ACP1 | P24666 | 2/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7569894 | 0.81 | HPRT1 (0.58) | HPRT1PNP | |
| SCHEMBL6673126 | 0.79 | ADORA2A (0.49) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL6676183 | 0.76 | PDE4A (0.53) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL5616439 | 0.75 | ADORA2B (0.49) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL6674167 | 0.75 | ADORA2A (0.43) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL6673901 | 0.74 | ADORA2A (0.52) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL6675396 | 0.73 | ACP1 (0.70) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5667530 | 0.73 | ADORA2A (0.61) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL6679184 | 0.73 | ADORA2B (0.51) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL6673671 | 0.73 | ADORA2B (0.55) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | ADORA2B 2136/4885ADORA2A 2027/4885PDE4A 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.